Presentations & Publications
2023 ASCO Annual Meeting
2023 AACR Annual Meeting
- A Phase 1 Study to Assess BDTX 1535, an Oral EGFR Inhibitor, in Patients with Glioblastoma or Non Small Cell Lung Cancer
- Discovery of BDTX-1535, a novel, brain penetrant, irreversible, potent, wild type sparing EGFR MasterKey inhibitor that targets oncogenic kinase domain mutations as well as extracellular domain alterations for the treatment of NSCLC and GBM
- Preclinical characterization of a brain penetrant RAF inhibitor, BDTX-4933, targeting oncogenic BRAF Class I/II/III and RAS mutations
34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
- BDTX-1535 is a Fourth Generation MasterKeyInhibitor of a Broad Spectrum of Intrinsic and Acquired Resistance Mutations of EGFR Expressed in NSCLC
- Anti-Tumor Activity of BDTX-1535, an Irreversible CNS Penetrant Inhibitor of Multiple EGFR Extracellular Domain Alterations, in Preclinical Glioblastoma Models
- Preclinical efficacy of BDTX-4933, a brain penetrant MasterKey inhibitor targeting oncogenic BRAF Class I/II/III mutations
33rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Pre-clinical evaluation of next-generation inhibitor targeting a wide spectrum of oncogenic BRAF dimers
- Discovery and characterization of selective, FGFR1 sparing, inhibitors of FGFR2/3 oncogenic mutations for the treatment of cancers
- BDTX-1535, a CNS penetrant MasterKey inhibitor of common, uncommon and resistant EGFR mutations, demonstrates in vivo efficacy and has potential to treat patients with NSCLC harboring osimertinib-resistant mutations with or without brain metastases
2021 American Society of Clinical Oncology Annual Meeting
- Clinical Pharmacokinetics of BDTX-189, an Inhibitor of Allosteric ErbB Mutations, in Patients With Advanced Solid Malignancies in MasterKey-01 Study
- Safety and Preliminary Efficacy From the Phase 1 Portion of MasterKey-01: A First-in-Human Dose-Escalation Study to Determine the Recommended Phase 2 Dose, Pharmacokinetics and Preliminary Antitumor Activity of BDTX-189, an Inhibitor of Allosteric EGFR/HE
American Association for Cancer Research Annual Meeting 2021
- CNS Penetrant, Irreversible Inhibitors Potently Inhibit the Family of Allosteric Oncogenic EGFR Mutants Expressed in GBM and Demonstrate Efficacy in Patient-Derived Xenograft Models
- Prospective Preclinical Modeling to Estimate Clinical Pharmacokinetics and Dose of BDTX-189, an Inhibitor of Allosteric ErbB Mutations in Advanced Solid Malignancies